Federico Innocenti
Senior Director, Clinical Development - Solid Tumors BeOne Medicines
Federico Innocenti, MD, PhD, is an oncologist and clinical pharmacologist specialized in clinical trials and early drug development in oncology. He served as Chair of the Gastrointestinal Solid Tumor Correlative Science Group in the Alliance for Clinical Trials in Oncology for 10 years. Dr. Innocenti spent collectively 20 years as a faculty at the University of Chicago and University of North Carolina. More recently, Dr. Innocenti joined AbbVie in the early development group in 2021 and subsequently BeOne Medicines in 2024 in the clinical development group for solid tumors working on RAS.
Seminars
Wednesday 9th September 2026
Panel Discussion: Setting the Boundaries of What’s Clinically Achievable in RAS Therapy Defining the Realistic Therapeutic Window for Next-Generation Strategies
3:30 pm
- How does differential targeting influence tolerability and depth of pathway inhibition, and where do selective versus broader approaches ultimately succeed or fail?
- How should mutant-selective versus wild-type-sparing strategies be balanced to deepen inhibition without breaching tolerability limits, especially when layering multi-agent regimens?
- How can safety-first design principles, PK/PD-guided exposure management, mechanism-based toxicity mitigation, and early integration of safety margins, enable continuous pathway suppression and long-term disease control?
